Ligand Pharma (LGND) - 500 Beiträge pro Seite

[IWA Japan]

Zum Unternehmen selbst:
Auf der Homepage http://www.ligand.com gibt es mehrere pdf-files zum Download, in denen man mit Informationen fast „erschlagen“ wird!
Ladet euch z.B. mal http://www.ligand.com/ir/LIGAR99.pdf herunter ( mit rechte Maustaste, Ziel speichern unter)

LGND verfolgt bei der Produktentwicklung eine Doppelstrategie:
Einerseits versucht man natürlich selbst, eignene Produkte zu entwickeln diese dann entsprechend zu vermarkten. Hierbei wurde bereits 3 Produkte von der FDA zugelassen, die sich alle bei verschiedenen Formen von Krebs angewendet werden!

Hinzu kommt zweitens noch die Produktentwickluing zusammen mit Partnerfirmen, wobei man für den hierbei erzielten Erfolg Lizenzgebühren für erzielte zukünftige Umsätze und Milestone-Zahlungen von den jeweiligen Firmen (z.B. Pfizer, Eli Lilly oder American Home Products) erhält. Hierbei liegen schon 2 Produkte in Phase III vor!

Entgegen von Analystenschätzungen bei Yahoo! Finance will die Firma deb Break-eben bereits 2000 erreichen, wobei dies ursprünglich schon 1999 geschehen sollte.

Hier noch die Piepeline in Bild (so gut es ging!)

eigene Produkte:


„Fremd“-Produkte:
Teil1

Teil2



Fazit: Habe zwar keine genauen UMsatzzahlen, aber wenn rein subjektiv sieht, was man für die gegenwärtige Marktkapitalisierung von 614 Mio $ geboten bekommt, ist wohl das große Potential von Ligand erkennbar. Vor allem ist zu bedenken, dass schon 3 Produkte auf dem MArkt sind und doiese somit sofort Umsätze erzielen!



hier noch der aktuelle Chart :
Ligand konnte den Abärtstrend seit März brechen und konsolidiert zur Zeit am Wiederstand bei knapp 14$.

[IWA Japan]

US-Impressionen:
I can`t speak for MJ or Henry. As for me, I just got tired of saying the same thing over and over about this company. That got boring to me and that`s the reason I haven`t posted as much as in previous months.
I still believe Ligand has a great chance of expanding its currently marketed drugs into larger indications. ONTAK for NHL and Targretin for psoriasis seems very likely. I really believe that will happen. I feel, relative to other biotech companies, Ligand has proven why you should be able to believe this company would be a safer bet. They do, after all, have 4 FDA approved drugs in 18 months, albeit for very small markets. Many of these other companies have given lots of promises and have been in the news, but they haven`t delivered yet and most never will. Ligand, on the other hand, has delivered! If Ligand can get prove efficacy in small markets and get their drugs approved, it`s not much of a stretch for me to think they can do it for larger markets.

As far as Targretin for ABC, I still think it`s possible and more likely than not to work, but not as likely as the other two options mentioned above.

The thing that makes me mad is how wrong Robinson is time and again about when these trials will be over and data will be released. Everyone is growing tired of waiting and some are losing faith as a result.

______________________________________________________________________________

Ligand Receives Approvable Letter from FDA for Targretin Gel; Approval Would Mark Fourth Product Approval for Ligand in Past 18 Months
SAN DIEGO--(BW HealthWire)--June 12, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter regarding the New Drug Application (NDA) for Targretin(R) (bexarotene) gel 1%, a novel therapy for the topical treatment of cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL) who have refractory or persistent disease after other therapies or who have not tolerated other therapies. Final FDA marketing approval of Targretin gel is pending final labeling agreement. Targretin gel, which was granted priority review status by the FDA, would be Ligand`s third approved product for CTCL and the first topical therapy approved by the FDA for CTCL.

Somit verfügt LGND bereits über 4 Marktprodukte

[Almöhi]

Hallo,

hört sich ja gut an ! nehme ich in meine watchlist auf !

da steckt noch potential drin ! andere bios sind schon zu gut gelaufen, um neu einzusteigen wie z.b. medarex, sequenum, celgene

oder was meinst du ?

gruß
almöhi

[IWA Japan]

ausgehend von der Tatsache, dass die größeren Werte wie MLNM;AFFX;HGSI;CRA; PDLI MEDX IDPH und wie sie alle heißen schon gut gelaufen sind, werden irgenwann auch die kleine kommen, ob dies schon demnächst so weit ist, weiß niemand, solange gilt erst mal die großenweiter laufen lassen.

Momentan versuche ich hier zusammen mit ein paar anderen, wie etwa epicuraul, eine derartige Strategie auszuarbeiten. Denn wenn es dann mit den kleine los geht, kann ich sofort handeln.

Die Vorstellung von LGND ist somit Teil dieser Strategie.
War auch schon mal im Aktionär, ist aber schon länger her - Juli 99!

[RCZ]

Ligand erhält O.K. für Targretin Gel

Ligand Pharmaceuticals Incorporated (Nasdaq:LGND, WKN:895777) gaben heute bekannt, dass die FDA (U.S. Food and Drug Administration) die Verkaufsfreigabe für Targretin® (bexarotene) gel 1% erteilt hat.
Targretin® nutzt ein neues Verfahren für die örtliche Behandlung von Hautverletzungen, für Patienten, die an Lymphgewebegeschüren leiden und bei denen andere Therapien nicht zum gewünschten Ergolg führten.
Targretin ist das vierte Produkt aus dem Hause Ligand. Mit dem Verkauf soll in den kommenden Wochen begonenn werden, wobei man auf die eigenen auf Onkologie und Dermatologie spezialisierten Verkaufskanäle zurückgreifen wird. Targretin wird einfach auf die Haut aufgetragen und ist so sehr leicht anzuwenden.

[traderdepot]

Hervorragender Thread !!
Weiter so, bin seit 22 € investiert und mir meiner Sache noch immer recht sicher.
Danke für die tollen Beiträge

MfG
Traderdepot

[IWA Japan]

[IWA Japan]

[IWA Japan]

hier fehlt noch der Chart

[ErnieEarn]

Hi Leute,

alles crasht so etwas vor sich hin und Ligand steigt...
any ideas???
Gruß und beste Kurse
EE

[IWA Japan]

Hier noch News aus dem Juli:
Monday July 17, 7:33 pm Eastern Time
Company Press Release
European CPMP Recommends Approval for Ligand`s Panretin Gel
First Product for Ligand Europe
SAN DIEGO--(BW HealthWire)--July 17, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND - news) announced today that the Committee for Proprietary Medicinal Products (CPMP) adopted a positive opinion recommending the grant of a Marketing Authorization for Panretin® gel (alitretinoin) 0.1% for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi`s sarcoma (KS). If granted final Marketing Authorization by the European Commission (EC), Panretin gel will be the first approved topical therapy in Europe for KS, the most common AIDS-related malignancy.

``We are pleased with the CPMP`s positive recommendation for the approval of the Marketing Authorization Application (MAA) for Panretin gel, the first of our European marketing submissions for four products which have now been approved in the US,`` said David E. Robinson, Ligand`s Chairman, President and CEO. ``We view Panretin gel as the first, though not the largest, building block of our European revenue stream. We expect to market this product directly in some countries, with existing partners Ferrer and Alfa Wassermann, and with additional new partners in other markets in Europe.``

Ligand submitted its MAA to the European Agency for the Evaluation of Medicinal Products (EMEA) in February 1999. The recommendation of the CPMP serves as the basis for approval by the EC, which would result in one single Marketing Authorization valid in all 15 Member States of the European Union. Typically, final EC approval is issued within three to four months of a positive CPMP opinion.

Ligand has agreements with Ferrer Internacional, S.A., to exclusively market and distribute Panretin gel in Spain, Portugal, Greece, and Central and South America and with Alfa Wassermann to exclusively market and distribute Panretin gel in Italy.

Basis for CPMP Recommendation

The MAA for Panretin gel was based on two multi-center, randomized, double-blind, vehicle-controlled, parallel group Phase III clinical trials, one conducted internationally at 17 sites in Europe, Australia and the U.S. and one conducted at 35 sites in North America. The patient response rate was evaluated using the AIDS Clinical Trials Group (ACTG) criteria for lesion response in KS. The overall response in the international study was 37 percent (clinical complete or partial response) for Panretin gel and 7 percent for the vehicle control group. Results of the North American trial demonstrated that 35 percent of patients treated with Panretin gel experienced complete or partial response compared to 18 percent of patients applying the vehicle gel. Both studies demonstrated statistically significant (p<0.002) superiority of Panretin gel compared to vehicle gel. Panretin gel was generally well tolerated, and the most common side effects, primarily mild to moderate, occurred almost exclusively at the site of application; side effects included, in most patients, erythema (redness) or skin irritation and, in some patients, pain, skin disorders, itching, flaking and stinging.

``If approved by the EC, Panretin gel will be the first specialist-prescribed, patient-applied treatment for AIDS-related KS in Europe, offering patients and physicians a non-invasive treatment option when currently available therapies have failed or are not appropriate,`` said Timothy Allington, President of Ligand`s European Operations. ``We will be working closely with the EMEA, the National Regulatory and Reimbursement authorities and our marketing partners to make this product available to patients in Europe as quickly as possible.``

Panretin gel and Kaposi`s Sarcoma

Panretin gel received U.S. Food and Drug Administration (FDA) approval in February 1999 for the topical treatment of cutaneous lesions in patients with AIDS-related KS. Ligand currently markets Panretin gel through its specialty oncology and dermatology sales force in the U.S. KS is the most common AIDS-related malignancy and is usually characterized by multi-focal, widespread lesions at the onset of illness. The disease may involve the skin, mouth, lymph nodes and visceral organs, such as the lung and gastrointestinal tract. Ligand estimates that KS affects 10,000 to 20,000 people in North America and Western Europe.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand has four drugs approved for marketing in the U.S. -- Targretin® (bexarotene) capsules, Targretin® gel, ONTAK® (denileukin diftitox) and Panretin® (alitretinoin) gel -- that are being marketed through its specialty cancer and dermatology sales force. Morphelan(TM), licensed from Elan, is currently under review by the FDA for marketing approval in the U.S. In Europe, a Marketing Authorization Application for Targretin capsules for the treatment of cutaneous T-cell lymphoma is currently under review. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IR) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand and actual results could differ materially from those described as a result of factors outside of the control of Ligand. There can be no assurance that the European Commission will approve Panretin gel or any other Ligand product in a timely manner or at all; that, if approved, Panretin gel or any other approved Ligand product will be accepted by physicians for prescribing, by patients for use and by insurance companies / agencies for reimbursement; or that Ligand will be able to successfully commercialize Panretin gel or any other product. Additional information concerning these and other factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Panretin® and Targretin® are registered trademarks of Ligand Pharmaceuticals Incorporated, and ONTAK® is a registered trademark of Seragen, Inc., a wholly owned subsidiary of Ligand. Morphelan(TM) is a trademark of Elan. Full prescribing information for Ligand`s products, including Targretin capsules, Targretin gel, ONTAK and Panretin gel, may be obtained in the U.S. from Ligand Professional Services by calling toll free 800-964-5836.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.

[ErnieEarn]

Hi IWA,

leider habe ich lange nix gehört zu Ligand, dummerweise kann ich auch keine INFOS bieten, wie sind Deine Einschätzungen? War das Gel die Info aus der Pipeline die zum Juli kommen sollte ??? Oder steht da noch was aus, die früheren KZ kann man wohl auch vergessen oder...
Gruß und beste Kurse
EE

[IWA Japan]

tja News gibts seitdem keine mehr

die AKtie läuft in keinster Weise, selbst als im Juli fast alle Bios deutlich zulegen konnten, konnte man mit LGND nix holen,

in ZUkunft wird vorerst wohl das gleiche passieren, trotz aussichstreicher Fundamental


wenn die Aktie entdeckt wird, dann könnte es deutlkioch aufwärts gehen, aber die Frage ist , ob sie entdeckt wird bzw. wann?



LGND zur Zeit nur spekulative Beimischung von der man keine stetige Kursentwicklung erwarten darf

[ErnieEarn]

kaum sucht man schon kommen diverse news dazu


Monday August 14, 4:24 pm Eastern Time
Press Release
Ligand Reports Results for Second Quarter and First Six Months 2000
Second Quarter Product Sales Up 154% and Net loss Per Share Down 25%
SAN DIEGO--(BUSINESS WIRE)--Aug. 14, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND - news) today reported revenues of $10.8 million for the second quarter ended June 30, 2000, a 27.9% increase over second quarter 1999, and $22.4 million for the first half ended June 30, 2000, a 20.0% increase over first half 1999 revenues.

Net loss for the second quarter 2000 was $16.5 million ($0.30 per share) compared to the net loss of $19.0 million ($0.40 per share) for the same period in 1999, representing an improvement of 13.3% (or 25.0% per share). For the first half of the year, net loss before debt conversion expense was $29.4 million ($0.54 per share) in 2000, compared to a net loss of $33.6 million ($0.73 per share) for the same period in 1999, representing an improvement of 12.4% (or 26.0% per share). Including the one-time charge for debt conversion, net loss for the first half 2000 was $31.4 million ($0.57 per share) compared to the net loss of $33.6 million ($0.73 per share) for the same period in 1999.

As of June 30, 2000, Ligand had cash, cash equivalents, short-term investments and restricted cash of $48.2 million, a decrease of $1.0 million from year-end 1999.

``Our burn rate and operating losses continue to decline as we expand our product sales and other revenues while continuing to maintain tight controls on overall expenses and all non-commercial expenses,`` said Paul V. Maier, Ligand Senior Vice President and Chief Financial Officer. ``Second quarter product revenues versus prior year reflect solid growth in ONTAK®, Targretin® capsules, and Panretin® gel, with the growth rate of ONTAK impacted early in second quarter by the launch and rapid penetration of Targretin capsules into the CTCL patient population. We expect product sales growth to further accelerate in the subsequent quarters of 2000, reflecting the effect of recent investments in expanded sales and marketing initiatives as well as the launch of Targretin gel initiated in early August. Furthermore, we anticipate other revenues to accelerate in the second half of the year, as certain other revenue items expected in the first half were delayed to the second half.

``We achieved important financial goals, as well, through the maintenance of cash balances ($48.2 million), continued expense discipline and the exercise of warrants, which strengthened cash and stockholders` equity with proceeds of $7.7 million.``

Highlights of second quarter of 2000 and recent events:

-- In June 2000, Ligand received FDA marketing clearance for

Targretin gel for the topical treatment of cutaneous lesions in

patients with early-stage cutaneous T-cell lymphoma (CTCL).

-- In May 2000, Ligand and Bristol-Myers Squibb entered into a

collaborative research agreement to focus on the discovery,

design, and development of orally active compounds that

selectively modulate the mineralocorticoid receptor and would be

useful in major cardiovascular diseases such as congestive heart

failure and hypertension.

-- In May 2000, positive clinical trial results for several Ligand

products were reported at the annual meetings and related

publications of the Society of Investigative Dermatology

(Targretin gel, Targretin capsules, ONTAK), the American Society
of Clinical Oncology (Targretin capsules), and the National Cancer

Institute`s International AIDS Malignancy Conference (Panretin

gel). Results of studies of Targretin capsules in non-small cell

lung cancer were announced by Ligand today in a separate press

release.

-- In June 2000, Ligand received $7.7 million from the exercise of

approximately 1.1 million of publicly traded warrants to purchase

shares of Ligand common stock that expired on June 3, 2000.

-- In June 2000, Ligand paid Elan Corporation, plc, $4 million in

stock as consideration for a milestone payment made to Elan for

Elan`s submission of a new drug application to the U.S. FDA for

Morphelan(TM) Rapid Onset Extended Release (ROER) capsules, a

once-daily, modified-release, oral dosage form of morphine for the

management of pain in oncology and HIV patients. Ligand has

certain marketing rights to Morphelan in the U.S. and Canada, and,

if approved, expects to launch Morphelan in first half of 2001.

-- In July 2000, the Committee for Proprietary Medicinal Products

(CPMP) adopted a positive opinion recommending the grant of a
Marketing Authorization for Panretin gel, which, upon final

approval, should facilitate commercialization within the EEC late

this year or early next.

Second Quarter and First Half Results

Total revenues for the second quarter ended June 30, 2000 of $10.8 million increased by $2.4 million, or 27.9%, compared to second quarter 1999 revenues of $8.4 million. The increase in second quarter revenues was primarily due to a $3.0 million increase in product sales. Total revenues for the first six months ended June 30, 2000, of $22.4 million increased by $3.7 million, or 20.0%, compared to first six months 1999 revenues of $18.7 million. The increase in the first six months revenues was primarily due to a $3.5 million increase in product sales.

Product sales showed strong increases in 2000 for the second quarter (154.3%) and first six months (55.0%) compared to the same periods in 1999. Increased ONTAK product sales and the launch of Targretin capsules in early 2000 accounted for the majority of the increase. ONTAK product sales increased by 86.1% to $3.1 million for the second quarter 2000 compared to $1.7 million for the second quarter 1999, and increased by 218.1% to $6.8 million for the first six months of 2000 compared to $2.1 million for the same period in 1999. ONTAK growth momentum in early second quarter was impacted by the rapid penetration of Targretin into the CTCL market, but by the end of the second quarter had absorbed that impact and regained momentum. Sales of Targretin® capsules were $1.2 million in the second quarter 2000, up 48% over the first quarter. Targretin capsules adoption rate accelerated significantly in the second quarter with new prescriptions nearly triple the first quarter, refill prescriptions up five-fold (nearly two hundred new patient prescriptions in June alone). While new prescriptions were strong, average dose per patient lagged due to physician experimentation in monotherapy and combination regimes, resulting in a slower translation to factory sales during the second quarter. Faster Targretin patient market penetration in the first half should translate to factory sales in the second half as average doses normalize and should provide a very positive market base as well for rapid Targretin gel market penetration. Panretin gel sales increased more than four-fold during the second quarter over the prior year from a small base, though continuing to be a secondary promotional priority after ONTAK and Targretin.

Similarly, cost of products sold increased to $2.0 million in the second quarter ended June 30, 2000, compared to $0.7 million for the same period in 1999, and to $4.1 million for the first six months ended June 30, 2000, compared to $2 million for the same period in 1999. As sales continue to grow, gross margins should continue to improve as the technology amortization component of cost of sales declines as a percentage of sales.

Research and development expenses decreased by $1.8 million (12.6%), to $12.8 million in the second quarter ended June 30, 2000, from $14.6 million in the same period in 1999, and decreased to $25.3 million in the first half of 2000, compared to $29.1 million in the same period of 1999, due primarily to the submission of new drug applications for Targretin capsules and Targretin gel in 1999 and their subsequent approvals in December 1999 and June 2000, respectively.

Selling, general and administrative expenses were $9.6 million in the second quarter ended June 30, 2000, up from $8.2 million in 1999. The increase, due primarily to increased selling and marketing costs associated with the expansion of the sales force from 20 to 40 representatives in late 1999 to support increased sales efforts, marketing activities related to the launch of Targretin capsules in January 2000 and continued promotion of ONTAK and Panretin gel, was more than offset by the decline in research and development expenses.

Loss from operations declined $3.2 million, or 19.1%, from $16.8 million in the second quarter ended June 30, 1999, to $13.6 million in the second quarter ended June 30, 2000, and declined $5.1 million, or 17.5 %, from $29.4 million in the first half ended June 30, 1999, to $24.3 million in the first half ended June 30, 2000.

Net loss for the second quarter 2000 was $16.5 million ($0.30 per share) compared to the net loss of $19.0 million ($0.40 per share) for the same period in 1999, representing an improvement of 13.3% (or 25.0% per share). For the first half of the year, net loss before debt conversion expense was $29.4 million ($0.54 per share) in 2000, compared to a net loss of $33.6 million ($0.73 per share) in 1999, representing an improvement of 12.4% (or 26.0% per share). Including the one-time charge for debt conversion, net loss for the first half of 2000 was $31.4 million ($0.57 per share) compared to the net loss of $33.6 million ($0.73 per share) for the same period in 1999.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties. Actual events or results may differ from Ligand`s expectations and reflect Ligand`s judgement as of the date of this release. There can be no assurance that Ligand will achieve future growth in product sales and earnings; that any compounds will be discovered or developed; that collaborative arrangements will be successful or continued; or that any products under development by Ligand or any of its collaborative partners will be successfully developed or marketed. Additional information concerning these and other risk factors affecting Ligand`s business can be found in press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s web site at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Note: Morphelan is a trademark of Elan Corporation, plc. Full prescribing information for our marketed products may be obtained from Ligand Professional Services by calling toll-free 800-964-5836.


LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)

Three Months Ended Six Months Ended
June 30, June 30,
2000 1999 2000 1999

Revenues:

Product sales $ 4,893 $ 1,931 $ 9,757 $ 6,297

Collaborative research
and development and other
revenues 5,878 5,559 12,684 11,178

Contract
manufacturing -- 931 -- 1,227

Total revenues 10,771 8,421 22,441 18,702

Operating costs and expenses:

Cost of products
sold 2,010 703 4,091 1,970
Contract
manufacturing -- 1,729 -- 3,044
Research and
development 12,766 14,612 25,264 29,082
Selling, general
and admin-
istrative 9,572 8,167 17,364 14,042

Total operating costs
and expenses 24,348 25,211 46,719 48,138

Loss from
operations (13,577) (16,790) (24,278) (29,436)

Interest income 686 525 1,427 1,275

Interest expense (3,204) (2,728) (6,664) (5,391)

Debt conversion
expense -- -- (2,025) --

Other, net (364) -- 126 --

Net loss $(16,459) $ (18,993) $ (31,414) $ (33,552)

Basic and diluted net
loss per share $ (0.30) $ (0.40) $ (0.57) $ (0.73)

Shares used in computing
net loss per
share 55,600 47,033 54,701 46,129

CONSOLIDATED BALANCE SHEETS
(in thousands)

June 30, December 31,
2000 1999
Assets (Unaudited)

Current assets:

Cash, cash equivalents and
short-term investments $ 46,492 $ 47,155
Other current assets 9,017 9,524

Total current assets 55,509 56,679

Restricted investments 1,724 2,011
Property and equipment, net 12,626 20,542
Acquired technology, net 42,446 38,969
Other assets 16,687 16,444

$ 128,992 $ 134,645

Liabilities and Stockholders` Deficit

Current liabilities $ 24,380 $ 20,701
Accrued acquisition obligation 2,700 2,900
Long-term portion of equipment
financing obligations 5,825 6,907
Convertible debentures and notes 112,896 129,727
Stockholders` deficit (16,809) (25,590)

$ 128,992 $ 134,645


Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.


--------------------------------------------------------------------------------
Contact:
Ligand Pharmaceuticals Incorporated
Paul V. Maier, Senior Vice President and Chief Financial
Officer, 858/550-7573


Email this story - View most popular stories emailed


--------------------------------------------------------------------------------
More Quotes and News: Ligand Pharmaceuticals Inc (NasdaqNM:LGND - news)
Related News Categories: biotech, earnings, health care, medical/pharmaceutical

--------------------------------------------------------------------------------

Help

Press Release
Targretin--R-- Capsules May Increase Survival in Patients with Non-Small Cell Lung Cancer
Follow-Up Results of Clinical Studies Support FDA Dialogue/Phase III Program
SAN DIEGO--(BW HealthWire)--Aug. 14, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND - news) today announced additional follow-up study results suggesting that Targretin® (bexarotene) capsules in combination with chemotherapy may increase survival in patients with non-small cell lung cancer (NSCLC). These results add to recently reported Phase II/III results and to a growing body of data that suggests Targretin therapy may, in some solid tumors, delay disease progression and extend survival.

Follow-up results from a Phase I/II trial of Targretin with a cisplatin-based chemotherapy regimen in patients with advanced NSCLC showed a 25% response rate and a 14-month median survival at the maximum tolerated dose (MTD) determined in the Phase I portion of the trial. Nine (32%) of the 28 patients remained alive at more than two years of follow-up. One-year survival by life table analysis was 61% and projected three-year survival was 30%.

``These results from this multi-center study are most notable in terms of the high survival rate, perhaps the best reported for Phase II trials of NSCLC, even though the tumor response rate is comparable to results of other Phase II platinum-based combination trials,`` said Steven D. Reich, M.D., Ligand`s Senior Vice President of Clinical Research. ``In the trials of patients with NSCLC reporting two-year survival rates, few have reported two-year survival rates better than 15%, which is less than half of the experience with Targretin for actual two-year survival and half of the projection for three-year survival. At the maximum tolerated dose of 400 mg/m2/day, Targretin showed substantial activity in combination with a third-generation NSCLC chemotherapy regimen with a tolerable safety profile.``

Previously reported results of a Phase II/III study of Targretin therapy in patients with advanced NSCLC who had prior treatment with platinum-based chemotherapy suggested a similar biological effect as demonstrated by a dose-responsive lengthening of time to progression. These studies build upon evidence provided by previously reported results of two Phase I/II studies of Targretin in patients with advanced cancers where the Principal Investigators of both studies noted stabilization of disease in a number of patients with NSCLC treated with Targretin monotherapy.

Andres Negro-Vilar, M.D., Ligand`s Senior Vice President of Research and Development and Chief Scientific Officer, said, ``Now that our Phase II studies have matured and we are able to look at survival data, we are excited by our findings. In addition to the survival data in our two NSCLC studies, we have recently assessed survival in our Phase I/II trial of Targretin as monotherapy in patients with head and neck cancer and our Phase I/II study in patients with advanced renal cell cancer with Targretin in combination with interferon, and we find a similar pattern. Compared to published literature in these patient populations, Targretin therapy appears to be adding to survival time. This body of evidence is now large enough that Ligand is compelled to proceed to dialogue with the FDA and European health authorities to agree upon the design of adequately powered Phase III studies in NSCLC to conclusively demonstrate this clinical benefit.

``There is growing evidence that novel chemotherapeutic or biological agents that are non-cytotoxic can provide survival advantage by mechanisms that do not necessarily involve tumor shrinkage. Preclinical and clinical studies indicate that Targretin belongs to this novel group of response modifiers with cellular activity that involves cell differentiation, inhibition of proliferation, and apoptosis with the resulting decrease in tumor malignancy and enhanced survival in a number of solid tumors.``

NSCLC Study: Targretin therapy in Combination with Chemotherapy Regimen

In a multi-center open-label Phase I/II trial, the administration of Targretin was combined with a chemotherapy regimen in patients who had not received prior chemotherapy for advanced NSCLC to determine the MTD and the response rate at MTD, median survival and one-year survival.

The study included 43 patients with Stage IIIB with pleural effusion or Stage IV NSCLC with Karnofsky Performance Status greater than 70.

In the Phase I portion of the trial, the dose of Targretin was escalated in cohorts of patients from 150 mg/m2/day through 600 mg/m2/day starting one week prior to commencement of the chemotherapy regimen of cisplatin (cycles of 100 mg/m2) along with vinorelbine (cycles of alternating doses of 30 mg/m2 and 15 mg/m2). Based on the 21 patients treated in this portion of the trial, the MTD of Targretin in combination with the chemotherapy regimen was determined to be 400 mg/m2/day.

In the Phase II portion of the trial, 28 patients were treated at the MTD, including all six who had received 400 mg/m2/day of Targretin during Phase I.

At MTD, seven (25%) of the 28 patients manifested a partial response including one with near complete resolution of all radiographic lesions. Median duration of treatment for this MTD group was 152 days (range: 13-259). Nine (32%) of the 28 patients remain alive with a minimum follow-up of two years. Median survival by Kaplan-Meier analysis in the entire Phase I/II study was 351 days (range: 19-1284), while median survival at MTD was 410 days, or 14 months (range: 55-1284). One-year survival by life table was 61% and projected three-year survival was 30%. Side effects observed in more than half the patients were asthenia, leukopenia, nausea, hyperlipemia, vomiting, headache, exfoliative dermatitis, and anorexia. Grade 3 (moderately severe) or 4 (severe) adverse events with an incidence of greater than 5% in either category without regard to relationship to Targretin therapy were hyperlipemia, leukopenia, nausea, vomiting, pneumonia, dyspnea, anemia, and asthenia. Grade 3 and 4 laboratory abnormalities with an incidence of greater than 5% in either category were decreased hemoglobin, white blood cells, absolute neutrophil counts, and absolute lymphocyte counts and increased prothrombin time, creatine, and amylase. Toxicities in the Phase II portion of the trial were consistent with Targretin monotherapy and with what one would expect with combination chemotherapy with cisplatin and vinorelbine.

NSCLC Study: Targretin Therapy following Chemotherapy Regimen

In a multicenter, randomized, double-blinded, placebo-controlled Phase II/III trial, the administration of Targretin was studied to determine whether high or moderate doses were more effective than placebo in postponing disease progression in patients with advanced NSCLC who were previously treated with platinum-based chemotherapy.

The study included patients with Stage IIIB with pleural effusion, Stage IV, or recurrent NSCLC who had stable or responsive disease following first-line, platinum-based combination chemotherapy. An interim assessment was scheduled after 90 patients had been enrolled, but the study was prematurely terminated for administrative reasons after 54 patients entered. Of the 54 patients, 52 received at least one dose of Targretin or placebo. Patients were randomized by center to placebo (16 patients, 31%), 300 mg/m2/day (21 patients, 40%), or 600 mg/m2/day (15 patients, 29%).

Median time-to-progression (TTP) from first treatment with Targretin was 56 days for placebo, 82 days for moderate dose, and 128 days for high dose (p=0.56, Log-rank). Patients who had a response to chemotherapy prior to receiving Targretin had longer TTP than those with stable disease.


Targretin Therapy following Chemotherapy Regimen
in Patients with Non-Small Cell Lung Cancer

Patient Category Placebo Targretin Therapy
300 mg/m2/day 600 mg/m2/day
Number of Patients,
% of Treated Patients 16, 31% 21, 40% 15, 29%
Number of Patients
Responsive to
Chemotherapy,
% of Patients in
Treatment Group 10, 63% 10, 48% 7, 47%

Time to Progression (Days)
All Patients 56 82 128
Responsive to
Chemotherapy 56 146 177

For patients who responded to chemotherapy, median TTP was 56, 146 and 177 days for placebo, moderate and high dose of Targretin, respectively. The percentage of patients with response to prior chemotherapy was higher in the placebo group (63%) than the active treatment arms (48%; 47%) suggesting that the effect on TTP is Targretin-related. Because of the small number of patients, the study does not have the statistical power to detect differences among the treatment groups. However, the study shows that patients with NSCLC can tolerate Targretin therapy at doses up to 600 mg/m2/day after platinum-based chemotherapy and that Targretin may have the potential to delay TTP in some patients with advanced NSCLC. Side effects observed were asthenia, hyperlipemia, skin scaling and dryness, peripheral edema, pruritus, anorexia, and dyspnea.

``Results indicate that higher doses of Targretin may potentially delay disease progression in non-small cell lung cancer patients,`` said Naiyer Rizvi, M.D., a medical oncologist at the Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C., and a Principal Investigator for the study. ``We are excited by these initial results and are hopeful that with further successful clinical research, Targretin may be added to the treatment for lung cancer, which is the leading cause of cancer death among men and women in the United States.``

The results of the study were published in the abstract ``Placebo-Controlled Trial of Bexarotene (Targretin, LGD1069), a Retinoid X Receptor (RXR) Agonist, as Maintenance Therapy for Patients Treated with Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): An L1069-20 Study Group Trial`` in the Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology.

Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer death for both men and women. The American Cancer Society estimates that 164,100 individuals will be diagnosed with lung cancer in 2000; of those, 131,200, or approximately 80%, will be diagnosed with NSCLC. The four stages of NSCLC are identified using the Tumor, Nodule, Metastasis (TNM) system, also known as the American Joint Committee of Cancer (AJCC) system. Early stage NSCLC is usually treated by surgery or radiation, sometimes combined with chemotherapy. The five-year survival rate for lung cancers treated by surgery before the cancer has spread to lymph nodes or other organs is about 42%. Less than half of patients with advanced stages of disease will survive one year, even with standard chemotherapy regimens.

Targretin Capsules

In December 1999, the U.S. Food and Drug Administration (FDA) approved Targretin for the treatment of all stages of CTCL refractory to at least one prior systemic therapy. The European Agency for the Evaluation of Medicinal Products (EMEA) is reviewing a Marketing Authorization Application submitted by Ligand in November 1999 for Targretin for the treatment of patients with CTCL.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect Ligand`s judgement as of the date of this release. Actual events or results may differ from Ligand`s expectations There can be no assurance that final results will be supportive of regulatory approvals required to market Targretin for NSCLC. Additional information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.


--------------------------------------------------------------------------------
Contact:
Ligand Pharmaceuticals Incorporated
Paul V. Maier
858/550-7573


Email this story - View most popular stories emailed


--------------------------------------------------------------------------------
More Quotes and News: Ligand Pharmaceuticals Inc (NasdaqNM:LGND - news)
Related News Categories: biotech, health care, medical/pharmaceutical

--------------------------------------------------------------------------------

Gruß und beste Kurse
EE

[IWA Japan]

tja hatte leider Pech mit dr Zeitüberschneidung


finde dennoch schade, ddass sich so wenige für LGND interssieren, s. Lesezugriffe

[ErnieEarn]

hi Leute,

hat jemand das Umsatzvolumen gestern gesehen......ist da was im Busch???? Sieht interessant aus...
Gruß und beste Kurse
EE

[RCZ]

die Resonanz von anderen Usern in einem qualitatriv hochwertigem Thread haut mich immer wieder um.
Die Resonanz in einem zugemülltem Thread ist meist höher

[IWA Japan]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[epicuraul]

erstmal ein großes kompliment an iwa!
so konsequent einen wenig beachteten thraed auf dem hohen niveau zu halten, verdient meinen vollen respekt.

so, nun will ich auch mal meinen teil dazu beitragen:
habe mal versucht herauszubekommen, warum der wert seit 1996 nicht gestiegen ist.
nachdem ich mir mal die zahlen der letzten 3 jahre angeschaut habe, ist es mir klar geworden.
ein wachstumswert scheint ligand nicht zu sein- zumindest in der bilanz.
100mio-118mio-74mio gewinn in jeweils den letzten 3 jahren. eine gradlinige gewinnsteigerung oder ein management, das diese erreichen könnte sind also nicht zu sehen.

dann scheint der wert mit 700mio mk wohl doch uninteressant für die fonds zu sein.

dann wird der wert aus (mir leider unbekannten gründen) als class b common stock an der nasdaq gelistet- klingt nicht nach ein qualitätsmerkmal.

zum letzten hat der wert ständig mit analystenschätzungen zu kämpfen, die mehr verfehlt als eingehalten werden konnten- sowas tut einem kurs nie gut.

ich persönlich würde einen wert mit größerem öffentlichen interesse bevorzugen, denn geld wird man mit ligand auf die schnelle nicht machen können.

gruß

[ErnieEarn]

hallo Leute,

vieleicht bewegt sich doch mal was ....hier die news
Press Release
Data Suggest Targretin Capsules May Improve Effectiveness of ONTAK Through Upregulation of IL-2 Receptor
Presentations at ISH 2000 Suggest Role of Drug in Combination Therapy and Report Australian Cohort Experience from Targretin Capsules and Gel Phase II - III CTCL Trials
SAN DIEGO--(BW HealthWire)--Aug. 29, 2000-- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - news) announced today that results of two studies of Targretin® (bexarotene) were presented at the 28th World Congress of the International Society of Hematology in Toronto, Ontario. In the first study presented, researchers concluded from in vitro data that Targretin capsules may improve the efficacy of ONTAK® (denileukin diftitox) for the treatment of patients with cutaneous T-cell lymphoma (CTCL). In the second presentation, researchers reported results from the Australian cohort of patients with CTCL in the Phase II - III clinical trials for Targretin capsules and gel.

In vitro studies done at Tufts New England Medical Center in Boston on leukemic cell lines demonstrated that Targretin was able to enhance the cytotoxicity of ONTAK. A Phase I-II evaluation of Targretin capsules in a cohort dose-escalation study is planned to measure modulation of Interleukin-2 receptor (IL-2R) expression in vivo after escalating doses of Targretin. The trial will assess the safety and tolerability of the combination of Targretin and ONTAK.

``It is becoming widely recognized that Targretin capsules and gel are effective treatments for patients with CTCL who have not benefited from other therapies,`` said Francine Foss, M.D., of Tufts New England Medical Center in Boston, Mass. ``Now we are beginning to see from our in vitro studies that Targretin may have an expanded role, possibly helping more patients with CTCL benefit from ONTAK and other systemic treatments.``

ONTAK, a targeted cytotoxic biologic, is a novel fusion protein comprised of IL-2 fragments genetically fused to portions of diphtheria toxin. ONTAK selectively kills cells bearing the high-affinity IL-2R by inhibiting protein synthesis through internalization of the diphtheria toxin. Although 65 percent of patients with CTCL express at least one component of the IL-2R, the response rate to ONTAK in published clinical trials has been 30 percent in patients whose malignant cells express the IL-2R.

Targretin is a RXR-selective retinoid which has been demonstrated in vitro to induce apoptosis (programmed cell death) and to upregulate expression of the high-affinity IL-2R. Targretin has demonstrated a 32 percent response rate as a single agent therapy in patients with refractory CTCL when treated at the recommended initial dose. Because clinical improvement with Targretin is most pronounced in the skin, Targretin may also affect cytokine expression by keratinocytes and accessory cells in the local milieu of the skin. Additional studies are needed to show if Targretin may also act synergistically when used in combination therapy with other systemic treatments, particularly ONTAK, and perhaps PUVA and photopheresis.

In the second presentation, Australian lead investigator H. Miles Prince, M.D., of St. Vincent`s and Peter MacCallum Hospitals in Melbourne reviewed the Australian experience from the Phase II - III studies with Targretin capsules and gel. These two dosage forms of Targretin were shown to be active and generally well tolerated in a cohort of Australian patients with CTCL who had failed other treatments. Researchers concluded that additional studies examining the role of Targretin in previously untreated patients are warranted.

``Targretin has proven to be an effective monotherapy for patients with difficult-to-treat disease,`` said Steven D. Reich, M.D., Ligand Senior Vice President, Clinical Research. ``We are hopeful that additional studies involving previously untreated patients will yield similar if not better results.``

The Australian Phase II-III studies of Targretin capsules and gel, led by Dr. Prince, involved eight patients: seven were treated with Targretin capsules and one with Targretin gel. Of the seven patients who started at 300 mg/m2/day Targretin capsules, five achieved a partial response, with mean time to onset response of 27 days. One patient with Sezary syndrome (an advanced hematological expression of CTCL) had a rapid and dramatic fall in blood Sezary cell (SC) count with apoptotic SCs visible following treatment with Targretin capsules. Three of five patients relapsed, with a mean time to relapse of 92 days. The major toxicity seen in patients treated with Targretin capsules was hypertriglyceridemia requiring therapy. One patient each discontinued treatment due to headache and edema. The patient receiving Targretin gel remains in partial response at 337 days.

Cutaneous T-Cell Lymphoma

Affecting an estimated 16,000 people in the U.S., CTCL is a form of non-Hodgkin`s lymphoma that results in circulating malignant T-lymphocytes (white blood cells involved in the body`s immune system). CTCL typically manifests itself initially in the skin, but over time may progress to involve other organs. CTCL is most commonly a slowly progressing cancer, and many patients live with the complications of CTCL for 10 years or more after diagnosis. Some patients, however, have a much more aggressive form of this disease, and the median survival for advanced-stage patients is less than three years.

Targretin Gel, Targretin Capsules, and ONTAK: A Comprehensive Portfolio for Early- to Late-Stage CTCL

Ligand Pharmaceuticals Incorporated provides clinicians and patients with a comprehensive portfolio of effective treatments for the management of CTCL. Ligand offers topical (Targretin gel), oral (Targretin capsules) and injectable (ONTAK) treatment options for appropriate patients suffering from CTCL. These three products are the first new agents approved for use in patients with CTCL in the last 10 years.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect Ligand`s judgement as of the date of this release. Actual events or results may differ from Ligand`s expectations. There can be no assurance that results of subsequent clinical studies of Targretin capsules or gel in conjunction with ONTAK or any other therapy for CTCL will confirm pre-clinical results or that Targretin will prove effective in combination therapy with ONTAK or any other drug. Additional information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.

Full prescribing information for Ligand`s products may be obtained in the U.S. from Ligand Professional Services by calling toll free 800-964-5836 or on Ligand`s website at http://www.ligand.com.


--------------------------------------------------------------------------------
Contact:

Ligand Pharmaceuticals Incorporated
Paul V. Maier, 858/550-7573


Email this story - View most popular stories emailed

Gruß und beste Kurse
EE

[IWA Japan]

@epicuraul:
1. also hab jetzt nicht nachgesehne, wann die Präparate zugelassen wurde, aber wohl erst in jüngerer Zeit, so dass man mit dieser konstanten UMsatzentwickluing nicht argumentieren kann...


2. die Enoistufunf als Class B stock dürfte wohl damit zusammenhängen, dass LGND nicht die Qualitätsmerkale der höheren Klassen erfüllt, so dass folglich instutionelle INvestoren von vorneherein Abstand nehmen.

Zwar bestehen fundamental ganz gute Aussichten für LGND, aber mal auf deutsch gesagt: Keien Sau interssiet sich so richtig für LGND.

Deshalb läuft der Kurs nicht und somit bietet sich hier auch keijne Investment an

[IWA Japan]

REVENUE
Quarters 1997 1998 1999 2000
MAR 9,812 5,066 10,281 11,669
JUN 9,916 4,386 8,421 10,771
SEP 10,172 3,947 9,765
DEC 21,799 4,274 12,428

Totals 51,699 17,673 40,895 22,440
Note: Units in Thousands of U.S. Dollars
andererseits ist dieUMsatzentwicklung wegen der bereits vermarkteten Präparate zimelich mies, muss mal gucken, woran das liegt...

[winetrader]

Wednesday June 20, 8:36 am Eastern Time
Press Release
Ligand Presentations at The Endocrine Society`s Annual Meeting Underscore Major Advances In Novel Tissue-Selective Steroid Receptor Modulator Compounds
Research in SERMs, SARMs, and Glucocorticoid Receptor Modulator is Highlighted
SAN DIEGO--(BW HealthWire)--June 20, 2001-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND - news) announced today that major scientific advances in three key research programs involving the estrogen, androgen and glucocorticoid receptors will be presented at the annual meeting of The Endocrine Society in Denver, Colorado. Two of these papers have been selected by The Endocrine Society to be showcased at the New Endocrine Therapies press conference on June 20, 2001, ``New Treatments for Breast Cancer, Osteoporosis, Inflammatory Diseases and Menopause.``

``Major advances in the development of tissue-selective steroid receptor modulators, including SERMs, SARMs and selective glucocorticoid receptor modulators, are a testimony to the powerful nuclear receptor technology, drug development focus and expertise that fuels Ligand`s strong research and development pipeline,`` said Andres Negro-Vilar, M.D., Ph.D., Senior Vice President of Research and Development and Chief Scientific Officer of Ligand.

``Each of these targets and the novel compounds we`re working on has the potential to bring to market blockbuster drugs for major therapeutic indications, such as osteoporosis, hormone replacement therapy, inflammatory diseases, male and female sexual dysfunction and central nervous system disorders such as Alzheimer`s and stroke.``

The first abstract, titled ``A Non-Steroidal, Selective Androgen Receptor Modulator (SARM) With Efficacy in Bone in the Orchidectomized Adult Rat`` (Abstract No. 40106), will present new data for LGD2226, a novel, small molecule, orally active SARM. LGD2226 was tested in long-term studies in animals deprived of androgens, a condition that mimics hypogonadism in humans. Androgen deprivation resulted in loss of bone mass, increased bone turnover and decreased bone strength, similar to what is seen in osteoporotic and aging males. LGD2226 prevented the increase in bone turnover, increased bone mineral density and bone mass and increased bone strength. These changes are consistent with an anabolic, bone-building effect which is not seen with antiresorptive agents (estrogen, bisphosphonates) currently used for the treatment of osteoporosis. In addition, LGD2226 had similar anabolic effects restoring muscle mass and, importantly, showed a greatly diminished impact on prostate growth, which enhances its therapeutic index when compared with current androgens.

In another abstract, titled ``A New Class Of Glucocorticoid Receptor-Dependent Non-Steroidal Anti-Inflammatory Agents`` (Abstract No. 41554), Jeff Miner, Ph.D., a Ligand scientist, discusses research that led to the identification and characterization of novel, orally active compounds that display full efficacy similar to widely used glucocorticoids (prednisone, dexamethasone) but have significantly reduced side effects. Corticosteroids provide therapeutic benefits in many inflammatory diseases, but the serious side effects that often ensue limit their use. Some of the most troubling side effects upon chronic use include osteoporosis and fractures, hyperglycemia and exacerbation of diabetes, hypertension and stunted growth in children. Using molecular and cellular models, the interaction of novel molecules with the glucocorticoid receptor (GR) was dissected out, allowing the identification of compounds that upon interaction with GR affect primarily the expression of genes that are central to obtain anti-inflammatory activity, while at the same time not reacting with other receptors and pathways that are involved in mediating the undesired side effects. Thus, these novel agents provide the opportunity to exploit their anti-inflammatory and antiproliferative properties and develop new therapies for inflammatory diseases such as rheumatoid arthritis and asthma, and oncological indications such as myelomas and leukemias.

A symposium (S-19) entitled, ``SERM Development: From First To Third Generation,`` highlights the progress in the development and clinical utilities of selective estrogen receptor modulators (SERMs), an area in which Ligand has established a clear leadership position. A presentation on second-generation SERMs will highlight the properties and advantages over first-generation products of the most advanced compound in late stage clinical development, lasofoxifene, a novel SERM resulting from a collaboration with Pfizer. Pfizer has moved this molecule into Phase III development for use in osteoporosis and hormone replacement therapy.

A presentation at this symposium by Dr. Negro-Vilar, entitled ``Third Generation SERMs: Partial Agonists with Full Benefits,`` will update Ligand`s research advances to develop further improved molecules that retain all the benefits of second-generation SERMs (i.e., bone activity equal to estrogens, no endometrial stimulation and protective of breast cancer) and add much needed full agonist effects in the central nervous system. These include suppression of vasomotor symptoms, improved mood and cognition and neuroprotection (Alzheimer`s, stroke). Using a combination of molecular, cellular and proven proof-of-concept animal models, novel classes of SERMs are emerging with the desired profile of activity and tissue selectivity.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect Ligand`s judgement as of the date of this release. Actual events or results may differ from Ligand`s expectations. There can be no assurance that LGD2226 or any compound or product in the Ligand pipeline will be successfully developed for osteoporosis, hormone replacement therapy, male or female sexual dysfunction or any other indication; that results achieved in animal models will be supportive of regulatory filings required to initiate human clinical trials; that results from more advanced clinical trials will be consistent with earlier results; that regulatory filings will be made and regulatory approvals will be granted in a timely manner or at all; that Ligand and/or its collaborative partners developing SERMs or SARMs will successfully develop any potential products; or that Ligand will be able to hire and retain qualified personnel. Additional information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s web site at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

[winetrader]

Monday June 25, 7:49 pm Eastern Time
Press Release
Ligand Pharmaceuticals and TAP Pharmaceutical Products Sign Collaborative Research Agreement
Compounds to Target Low Testosterone, Male and Female Sexual Dysfunction, Osteoporosis
SAN DIEGO--(BW HealthWire)--June 25, 2001-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND - news) and TAP Pharmaceutical Products Inc., announced today the initiation of a joint research and development alliance that will focus on the discovery and development of selective androgen receptor modulators (SARMs). SARMs contribute to the prevention and treatment of certain diseases, including hypogonadism (low testosterone), male and female sexual dysfunction, male and female osteoporosis, frailty, and male hormone replacement therapy (HRT).

``We hope the partnership of Ligand`s SARM discovery leadership, innovative technology and advanced compounds together with TAP`s development, sales and marketing expertise will enhance our ability to serve patients and physicians in the areas of urology, gynecology and endocrinology through the development of innovative new therapies,`` said John Seely, Ph.D., Vice President of Research and Development at TAP. ``We view this collaboration with Ligand as an opportunity to access some exciting new strategic growth markets for our company.``

Under the terms of the agreement, TAP has been granted exclusive worldwide rights to manufacture and sell any products resulting from the collaboration in its field, including treatment and prevention of hypogonadism, male sexual dysfunction, female osteoporosis, male HRT and other indications not retained by Ligand. Ligand may receive up to $44 million in research funding and milestones (if two products are successfully developed), including a near-term milestone of $3.5 million pertaining to LGD2226, Ligand`s current lead SARM. An investigational new drug application (IND) for LGD2226 could be filed as early as next year. Ligand may also receive up to double-digit royalties as compounds are developed and commercialized. The three-year collaboration carries an option to extend the agreement by up to two additional one-year terms. Ligand retains certain rights in the androgen receptor field, including the prevention or treatment of prostate cancer, benign prostatic hyperplasia, acne, and hirsutism. In addition, Ligand has an option at the expiration of the initial three-year term to develop one compound and a backup not being developed by TAP in its field, with TAP retaining an option to negotiate to co-develop and co-promote such compounds with Ligand.

``We are delighted to enter into this collaboration that allows us to accelerate the development and commercialization of our SARM technology and leading products,`` said Andres Negro-Vilar, Senior Vice President, Research and Development and Chief Scientific Officer at Ligand. ``Our advanced molecules showing anabolic activity in bone and muscle, positive effect on libido and reduced prostate stimulation will synergize with TAP`s focus in key therapeutic areas that are ideal targets for SARMs. We believe that we have progressed in this area over the past five years to the point where we are poised to achieve in the SARM field what we are achieving with our second and third generation selective estrogen replacement modulators.``

SARMs, a novel class of orally active non-steroidal molecules that target modulation of the androgen receptor, are designed to enhance the beneficial effects of androgen receptor activation while reducing or eliminating the undesired side effects. The use of currently available oral androgens has been limited due to safety concerns related to liver toxicity. Ligand believes LGD2226 represents the first SARM for the treatment of major androgen-related diseases and disorders, such as hypogonadism, female osteoporosis, male hormone replacement, male and female sexual dysfunction, and cachexia (wasting). As a result of their potential to build bone while preventing bone loss, these novel SARMs represent important new therapeutic opportunities for the treatment of both male and female osteoporosis. These agents also show distinct promise for the treatment of sexual dysfunction, not only in hypogonadal elderly males but, importantly, in women. The combined activity of restoring sexual drive in postmenopausal women while providing anabolic activity in bone, alone or in combination with estrogen replacement therapy, would address a large unmet market need.

TAP Pharmaceutical Products Inc.

TAP Pharmaceutical Products Inc., located in Lake Forest, Illinois, is a joint venture between Abbott Laboratories, headquartered in Abbott Park, Illinois, and Takeda Chemical Industries, Ltd., of Osaka, Japan. TAP markets Lupron Depot® (leuprolide acetate for depot suspension) for palliative treatment of advanced prostate cancer, management of endometriosis, anemia caused by uterine fibroids in combination with iron, and central precocious puberty and Prevacid® (lansoprazole) for the treatment of various acid-related disorders including gastroesophageal reflux disease (GERD) and ulcers.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand and TAP which involve risks and uncertainties and reflect the parties` judgement as of the date of this release. Actual events or results may differ from these expectations. There can be no assurance that the collaborative agreement will be successful or continued; that Ligand will receive any future payments for the discovery, development and/or commercialization of LGD2226 or any SARM compound; that results of clinical studies of LGD2226 or any development candidate identified as a result of the TAP/Ligand collaboration will be successfully developed; that any SARM compound will be successfully commercialized alone or in collaboration with TAP.

Additional information concerning these and other risk factors affecting Ligand`s or TAP`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s web site at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. For more information on TAP, please visit http://www.tap.com.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.